- Showing 1–12 of 12 items
Microneutralization end point–dilution assays were performed at ZeptoMetrix. SARS-CoV-2 virus, isolate USA-WA1/2020, NR-52281 (CDC and BEI Resources, National Institute of Allergy and Infectious Diseases, NIH) was used for microneutralization end point–dilution assays.
New ZeptoMetrix® NATtrol™ SARS-CoV-2 Omicron Control Now Available
ZeptoMetrix® launches the SARS-CoV-2 Omicron Control. Now available for pre-order.
ZeptoMetrix® Launches New Ready-to-Use SARS-CoV-2 Delta Variant Molecular Quality Controls.
Rheonix utilizes ZeptoMetrix reagents to advance rapid diagnostic COVID-19 testing.
This podcast series highlights career insights from pharmaceuticals and health science experts.
ZeptoMetrix® supports NovaSterilis in achieving EUA for the Nova2020™ system in decontaminating select N95 respirators.
FDA suggests ZeptoMetrix® test materials for SARS-CoV-2 assay validation.
ZeptoMetrix® and the University of Buffalo are leveraging resources to develop new quality control products for infectious disease diagnostics.
ZeptoMetrix® newly inactivated and non-infectious NATtrol™ SARS-CoV-2 Recombinant is available for sale
IDbyDNA Announces Agreement with ZeptoMetrix to Support Quality Control Products.
ZeptoMetrix® Corporation names Shawn R. Smith it's new President and Chief Executive Officer.